semaglutide masld 📘 AASLD adds to practice guidance: Key updates The AASLD has updated its MASLD practice guidance to formally include semaglutide as a treatment option for adults with MASH and F2–F3 Metabolic Dysfunction–Associated Steatotic Liver Disease

2022;doi:10.1111/dom.14725.

CBD doesnt bind directly to CB1 or CB2 receptors but influences them indirectly, supporting the bodys natural processes.* CB1 receptors are particularly important for sleep regulation, as they influence neural activity and circadian rhythms

Liu H, Sridhar VS, Perkins BA, Rosenstock J, Cherney DZI (2022) SGLT2 inhibition in type 1 diabetes with diabetic kidney disease: potential cardiorenal benefits can outweigh preventable risk of diabetic ketoacidosis

More than one-half of individuals with severe mental illnesses are obese or overweight, 1 resulting from multiple factors that may include psychiatric symptoms (eg, anergia and hyperphagia), poor dietary choices, sedentary lifestyle, underlying inflammatory processes, medical comorbidities, and iatrogenic consequences of certain medications

Despite important knowledge gaps in our understanding of IR in T1D, targeting IR in overweight/obese patients with T1D may decrease the risk of diabetes complications, contribute to weight loss, and improve glycemic control